A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Luckily for you, we built StockStory to help you separate the good from the bad. Keeping that in mind, here is one cash-producing company that leverages its financial strength to beat its competitors and two that may struggle to keep up.
Two Stocks to Sell:
Knowles (KN)
Trailing 12-Month Free Cash Flow Margin: 14.8%
With roots dating back to 1946 and a focus on components that must perform flawlessly in critical situations, Knowles (NYSE:KN) designs and manufactures specialized electronic components like high-performance capacitors, microphones, and speakers for medical technology, defense, and industrial applications.
Why Do We Pass on KN?
- Annual sales declines of 5.2% for the past five years show its products and services struggled to connect with the market during this cycle
- Modest revenue base of $614.1 million gives it less fixed cost leverage and fewer distribution channels than larger companies
- Earnings growth over the last five years fell short of the peer group average as its EPS only increased by 5.2% annually
Knowles is trading at $30.75 per share, or 23x forward P/E. If you’re considering KN for your portfolio, see our FREE research report to learn more.
Baxter (BAX)
Trailing 12-Month Free Cash Flow Margin: 3%
With a history dating back to 1931 and products used in over 100 countries, Baxter International (NYSE:BAX) provides essential healthcare products including dialysis therapies, IV solutions, infusion systems, surgical products, and patient monitoring technologies to hospitals and clinics worldwide.
Why Do We Avoid BAX?
- Constant currency revenue growth has disappointed over the past two years and shows demand was soft
- Performance over the past five years shows each sale was less profitable, as its earnings per share fell by 6% annually
- Low returns on capital reflect management’s struggle to allocate funds effectively, and its decreasing returns suggest its historical profit centers are aging
At $18.03 per share, Baxter trades at 9.5x forward P/E. Dive into our free research report to see why there are better opportunities than BAX.
One Stock to Watch:
Braze (BRZE)
Trailing 12-Month Free Cash Flow Margin: 7.9%
With its technology powering interactions with 6.2 billion monthly active users across the digital landscape, Braze (NASDAQ:BRZE) provides a platform that helps brands build and maintain direct relationships with their customers through personalized, cross-channel messaging and engagement.
Why Does BRZE Stand Out?
- Billings have averaged 28% growth over the last year, showing it’s securing new contracts that could potentially increase in value over time
- Estimated revenue growth of 20.3% for the next 12 months implies its momentum over the last two years will continue
Braze’s stock price of $23.68 implies a valuation ratio of 2.8x forward price-to-sales. Is now the right time to buy? Find out in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.